RxDoctor Payments Data

Rajan Shah, MD

Clinical Cardiac Electrophysiology · Stanford, CANPI 1679833867

Payments from drug & device makers

$37,868in general payments, 2019–2025

Across 256 payments — averaging $147.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$25K
  • Abbott$7K
  • Medtronic$5K
  • Biosense Webster, Inc.$901
  • Atricure, Inc.$659
  • Biotronik Inc.$111
  • plus $71 from 3 others

What the payments were for

  • Consulting fees$12,98134%
  • Speaking & faculty fees$10,00026%
  • Travel & lodging$4,48012%
  • Food & beverage$10,26727%
  • Education$1400%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Boston Scientific90$24,768
Abbott91$6,724
Medtronic(2 entities)40$4,635
Biosense Webster, Inc.23$901
Atricure, Inc.8$659
Biotronik Inc.1$111
EBR Systems, Inc.1$36
Irhythm Technologies, Inc.1$24
E.r. Squibb & Sons, L.L.C.1$11

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$37,868 in reported general payments places this provider in the 45th percentile of 290 clinical cardiac electrophysiology providers in California.

See all clinical cardiac electrophysiology providers in California

Medicare billing

Part B allowed, 2024
$338,200
Medicare patients
913
Services billed
3,213

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban163$180,379
XareltoRivaroxaban49$56,485
MultaqDronedarone Hcl24$36,530
EntrestoSacubitril/Valsartan15$15,090
Mexiletine Hcl11$1,421
Metoprolol Succinate96$1,381
Amiodarone Hcl63$1,285
Flecainide Acetate24$734
Rosuvastatin Calcium13$589
Spironolactone41$416
Losartan Potassium43$321
Carvedilol31$316
SotalolSotalol Hcl15$278
Metoprolol Tartrate26$272
Sucralfate14$268

Paid to pharmacies, not to this prescriber.

Other clinical cardiac electrophysiology in Stanford

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →